Orrick Advises Cortexyme on $75 Million IPO
| May.09.2019
Orrick has advised San Francisco-based biopharmaceutical company Cortexyme on its $75 million initial public offering of 4.412 million shares of ...
Helping life
sciences
companies
innovate
and grow
Life Sciences Sector
Our Life Sciences practice is built around our core commitment to support the development of technology that improves lives.
Client Results
Orrick Advises Twist Bioscience on $78.8 Million Follow-On Offering
| May.09.2019
Orrick has advised San Francisco-based synthetic biology company Twist Bioscience (NASDAQ: TWST) on its $78.8 million follow-on offering of 3.750 ...
Orrick Advises PhyNexus on Acquisition by Biotage
| December.05.2018
Orrick has advised Silicon Valley-based PhyNexus on its acquisition by Biotage AB, a Swedish public company.
Orrick Tech Companies Team Advises Cortexyme in $76 Million Series B Financing
| June.06.2018
Orrick has advised Cortexyme, a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s and other ...
Orrick Advises Underwriters in $172.5 Million Follow-on Offering by Intercept Pharmaceuticals
| April.09.2018
Orrick represented Credit Suisse and Jefferies as underwriters for a follow-on public offering of 2,695,313 shares of common stock by Intercept ...
Orrick Team Plays Key Role in Securing Trademark Win for Client CoorsTek in Paris High Court
| March.12.2018
An Orrick team was instrumental in securing a favorable ruling from the Paris High Court on behalf of client CoorsTek in ongoing trademark litigation ...
Orrick Advises SIMICON on Sale to Mesa Laboratories
| November.06.2017
Orrick advised the founding shareholder of SIMICON GmbH on the sale of the company to Mesa Laboratories, Inc., a U.S. technology innovator.
Orrick Represents Underwriter in Axsome Therapeutics’ Follow-on Offering
| April.03.2017
Orrick advised Ladenburg Thalmann & Co. Inc., the underwriter and sole book-running manager, on the follow-on offering by Axsome Therapeutics.
Orrick Advises Deutsche Beteiligungs AG on Investment in Radiology Group
| March.30.2017
Deutsche Beteiligungs AG (DBAG) invests in two radiology practices in the state of North Rhine-Westphalia, Germany, and will merge them into a group.
Orrick Advises Otsuka Pharmaceutical in Acquisition of Neurovance
| March.02.2017
Orrick is advising Otsuka Pharmaceutical Co. , a major Japanese pharmaceutical company, on its acquisition of Massachusetts-based Neurovance, Inc.
Insights
Dusting the Regulatory Framework – French Competition Authority Seeks to Liberalize Distribution of Drugs and Private Medical Biology
by Marie-Laure Combet and Elise Durand | April.26.2019
On April 4, 2019, just three months after the publication of the European Commission (EC) report on “Competition enforcement in the pharmaceutical ...
Profiles in Innovation: Twist Bioscience’s Co-Founder Navigates Company from Start-up to Public Company
| February.21.2019
Emily Leproust discusses her inspiration and journey building a public company in the fast growing synthetic DNA market with commentary from Orrick ...
Scope of Estoppel Post-IPR Proceedings Becoming Clearer
by K. Patrick Herman | March.27.2017
This estoppel provision has been the subject of a number of Federal Circuit and district court decisions.
HALLOWEEN TREAT: Judge’s October 31 Order Adds $21 Million to Jury’s $70 Million Award for Trade Secret Theft
by Mona S. Amer | November.22.2016
On October 31st of this year, a district judge in Massachusetts granted a motion for enhanced damages in a theft of trade secrets case, adding an ...
Confidential Settlement Amounts Are Not Necessarily Confidential
| June.10.2016
Courts in the Northern District of California, which have been handling price-fixing class actions in the electronics industry for more than a ...
Supreme Courts Request for Views of the United States on Cert Petition in Lamictal ReversePayment C
by Robert Reznick | June.09.2016
On Monday, June 7, the Supreme Court requested the views of the Solicitor General in connection with a petition for certiorari filed by the U.S. ...
Third Circuit Rejects Drug Manufacturer’s Single-Product Bundling Claim – But Prescription for the Future Is Unclear
by Ellen Shulock Caro, Russell P. Cohen and Howard Ullman | May.19.2016
You know what they say: one man’s price is another man’s bundle. No? Well maybe they should, after this recent decision out of the Third Circuit in ...
Quo Vadis FTC: What Does the Commission's Complaint Against Endo Pharmaceuticals and Others Say About the Future of Post-Actavis Hatch-Waxman Litigation and Reverse Payment Settlements?
by Robert Reznick | April.07.2016
This alert, the title of which is adapted from a March 30, 2016 FTC Staff Attorney blog post, considers the FTC’s first lawsuit challenging a ...
Post-Grant Proceedings Complicate Pharmaceutical Litigation
| April.04.2016
Since the passage of the America Invents Act in 2011, various changes to the patent litigation landscape have occurred.
District Court Finds No Personal Jurisdiction over Swedish Manufacturer of Pharmaceutical Product That Knew its Products Were Resold to U.S. Customers
| January.05.2016
Novotec Pharma LLC, v. Glycobiosciences, Inc., U.S. District Court for the District of New Jersey, January 5, 2016
The complicated history of this ...
Orrick Lands Weil Gotshal Life Sciences Ace In NY
| December.15.2015
Law360 covers life science litigator Kathy O'Connor's move to Orrick.
When asked about her reasons for choosing Orrick, Kathy said, “Orrick does ...
Eight Product-Hopping Takeaways from Namenda Ruling
by Robert Reznick and Howard Ullman | June.11.2015
Orrick attorneys co-author an article on the Second Circuit's affirmation of a preliminary injunction in New York v. Actavis and what aspects of the ...
News
Orrick Grows Life Sciences Team
| April.09.2019
Orrick announced today that Stephen Thau, a leading advisor to life sciences and other tech companies, has joined the firm as a partner, based in ...
Orrick Expands New York Corporate Group With Addition of M&A Partner David Schwartz
| April.16.2018
Orrick announced today that David Schwartz has joined the firm as a partner in New York.
Orrick’s Technology Companies Practice Expands into Seattle
| January.11.2017
Orrick announced today that Blake Ilstrup has become a Partner of the firm and leader of its Technology Companies Group in Seattle.
Antitrust Watch Blog
In-depth analysis and commentary on major developments in global antitrust and competition law
"Enjoys a fine reputation for its work in the technology and life sciences arenas.”
2016 Chambers USA - Capital Markets (California)
The World in U.S. Courts
A quarterly review of the most important decisions applying U.S. law to global business and cross-border activities.
Some of the recognition we have received
IP Group of the Year
Law360, 4 times
Tech Group of the Year
Law360, 2018 and 3 times
Employment Group of the Year
Law360, 2018 and 3 times
Recommended
Global Competition Review 100, 2019
IP Litigation Department of the Year
The American Lawyer, 2016
Top 5 Litigation Powerhouse
Law360, 2016
Litigation Power Rankings – Top 10
The American Lawyer, 2016
Appellate Hot List
National Law Journal, 2018 and 7 times
Litigation Department of the Year
The Recorder, 2016 and 2 times
Labor & Employment Defense Firm of the Year
The Recorder, 2017 and 4 times
International IP Firm of the Year
China Law & Practice, 2015
Tier 1 for China Patent Work
Asian Legal Business, 2013-2018
China Foreign Law Firm of the Year
Managing IP, 2016